On April 4, 2014, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that its phase 2 trial enrollment and dosing for PEGPH20 has come to a halt, driving its stock price down more than 31% in pre-market trading. The stock is trading down 30% as of 1 pm EST. Halozyme Therapeutics, Inc. (NASDAQ:HALO), shares after opening at $7.41 moved to $8.01 on last trade day and at the end of the day closed at $7.42. Company price to sales ratio in past twelve months was calculated as 16.79 and price to cash ratio as 12.87. Halozyme Therapeutics, Inc. (NASDAQ:HALO), showed a negative weekly performance of 11.98%.
Imperva Inc. (NYSE:IMPV) announced after the close Wednesday that it now expects to report first quarter revenues of $31.0 million to $31.5 million, down from its prior forecast of $36.0 million to $37.0 million. The company expects to report a non-GAAP loss of $0.44 to $0.40 per share. Prior expectations had been for a loss of $0.37 to $0.33. The stock is now down 16.73 on 519K shares. Imperva Inc (NYSE:IMPV), shares advanced 0.39% in last trading session and ended the day on $28.11. Imperva Inc (NYSE:IMPV), return on equity ratio is recorded as -29.80% and its return on assets is -15.80%. Imperva Inc (NYSE:IMPV), yearly performance is 59.28%.
GIGAMON INC (NYSE:GIMO): Stock crashed 34% yesterday to close at $17.31 due to weak first quarter results. The volume traded was a record 8.6 million. The stock has been in a downtrend over the past 2 weeks supported by an MACD (12, 26, 9) signal crossover & zero crossover. The RSI (14) just entered oversold level at 17.60 and looks to remain there. The long-term trend looks downward, though the stock can swing back to Fibonacci pivot level of $30.29 only if supported by volume and if it reaches previous support at $21.55 (S1). The stock can be short intra-day for target $16.17 (S2) with stop-loss at $18.60. Gigamon Inc (NYSE:GIMO), shares moved down 3.27% in last trading session and was closed at $16.27, while trading in range of $ 16.22 – 17.06. Gigamon Inc (NYSE:GIMO), year to date (YTD) performance is -42.06%.
Controladora Vuela Co Avcn SA CV (NYSE:VLRS), the ultra-low-cost airline serving Mexico and the US, on 9 April reported its preliminary traffic results for March 2014. Controladora Vuela Co Avcn SA CV (ADR) (NYSE:VLRS) stock on April 10, 2014 reported a decrease of -4.20% to the closing price of $7.07. Its fifty two weeks range was $6.90 – $15.94. The total market capitalization recorded 810.15 million. The overall volume in the last trading session was 877,200 shares. In its share capital, company has 88.77 million outstanding shares. Controladora Vuela Co Avcn SA CV (ADR) (NYSE:VLRS), weekly performance is -12.27%. On last trading day company shares ended up $7.01. Controladora Vuela Co Avcn SA CV (ADR) (NYSE:VLRS), distance from 50-day simple moving average (SMA50) is -27.02%. Analysts mean target Price for the company is $12.80.
Leave a Reply